Lipoxen to develop a super-generic ribavirin
This article was originally published in Scrip
A super-generic nanoparticle formulation of ribavirin which is targeted to the liver will be the first product worked on by a new collaboration between the AIM-listed firm Lipoxen and researchers at the University of Nottingham in the UK.
You may also be interested in...
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.